CLDN8 and breast carcinoma: Collectively, these findings underscore the potential of CLDN8 as a marker of favorable prognosis in ER(−) breast cancer, while also highlighting the complexity of its role across various breast cancer subtypes, thus necessitating additional research to elucidate its clinical utility.